1. Scrip
  2. >>Business
  3. >>Deals

Gilead Moves Into Microbiome In Deal With Second Genome

 
• By Joseph Haas

Gilead lands on Second Genome as its first partner to apply microbiome analysis to pipeline assets to look for biomarkers. Companies also team up on GI drug discovery.

Biofilm - Microbiome - Abstract 3D Illustration
Second Genome will apply its microbiome screening technology to existing Gilead pipeline assets

Gilead Sciences Inc. has been looking for a way into microbiome research for a while, and following a competitive process, settled on a four-year collaboration with Second Genome Inc. to identify biomarkers of clinical response in inflammation, fibrosis and other therapeutic areas. Additionally, the companies will partner to discover new targets and drug candidates for inflammatory bowel disease (IBD) indications.

Gilead selected Second Genome after assessing the technological capabilities of several microbiome-focused biotechs, Gilead senior vice president of research external innovation Linda Higgins said in an interview. The deal, announced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

More from Business